Subject characteristics
| Variable | Patients (n = 153) | Controls (n = 87) | p Value |
|---|---|---|---|
| Values are means (SD) unless stated otherwise. | |||
| *The mean daily dose of frusemide equivalent at enrolment is given. | |||
| ACEi, angiotensin converting enzyme inhibitor; AF, atrial fibrillation; AIIA, angiotensin II inhibitor; LVEDV, left ventricular end diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end systolic volume; NYHA, New York Heart Association functional class; pV˙o2, peak oxygen consumption; SR, sinus rhythm; V˙e/V˙co2 slope, slope relating ventilation to carbon dioxide production. | |||
| Age (years) | 66 (11) | 66 (11) | 0.52 |
| Height (cm) | 172 (8) | 170 (10) | 0.31 |
| Weight (kg) | 80.0 (15.2) | 74.2 (11.1) | 0.04 |
| Body surface area (kg/m2) | 1.9 (0.2) | 1.8 (0.4) | 0.40 |
| Rhythm (SR/AF) | 104/49 | 87/0 | |
| Drugs | N/A | ||
| Frusemide (furosemide)* | 64.4 (26.2) | ||
| ACEi/AIIA (%) | 88 | ||
| Spironolactone (%) | 22 | ||
| β Blocker (%) | 44 | ||
| NYHA class I/II/III/IV (n) | 2/99/48/2 | ||
| LVEF (%) | 34.9 (6.3) | 60.5 (6.4) | <0.0001 |
| LVEDV (ml) | 227 (72) | 99 (24) | <0.0001 |
| LVESV (ml) | 150 (59) | 39 (12) | <0.0001 |
| Exercise time (s) | 491 (212) | 818 (189) | <0.0001 |
| pV˙o2 (ml/kg/min) | 21.6 (5.6) | 35.2 (7.5) | <0.0001 |
| V˙e/V˙co2 slope | 35.7 (8.1) | 27.0 (2.8) | <0.0001 |